Skip to main content
. 2022 Dec 17;12:11014. doi: 10.7189/jogh.12.11014

Table 3.

Pooled survival rates (%) of gastric cancer in retrospective and prospective

Categories One-year
Two-year
Three-year
Five-year


N
SR (95% CI)
N
SR (95% CI)
N
SR (95% CI)
N
SR (95% CI)
Histological type
GA
64
71.7 (68.0-75.4)
33
54.7 (46.5-62.9)
58
52.6 (47.8-57.5)
69
45.0 (40.0-50.0)

SRCC
2
66.8 (59.3-74.3)
NA
NA
3
38.2 (3.7-72.6)
2
28.7 (0-83.6)

MC
1
99.0 (85.2-112.8)
NA
NA
1
50.0 (0-119.3)
2
33.8 (0-100.4)

Tubular
NA
NA
NA
NA
NA
NA
1
56.0 (52.4-59.6)










TNM stage
I
16
98.4 (97.4-99.3)
5
81.0 (67.6-94.5)
25
91.3 (88.6-94.0)
41
83.9 (81.2-86.7)

II
19
94.2 (92.2-96.3)
8
73.2 (61.7-84.7)
28
73.2 (68.5-77.9)
45
61.5 (58.0-64.9)

III
26
80.6 (77.0-84.3)
13
54.0 (36.5-71.5)
35
43.6 (39.8-47.4)
56
31.9 (28.9-34.8)

IV
32
54.2 (45.9-62.5)
18
24.6 (15.7-33.5)
25
12.3 (8.1-16.5)
28
9.1 (6.5-11.7)

I/II
4
95.9 (92.7-99.2)
1
96.0 (91.5-100.5)
6
71.0 (54.0-88.0)
13
65.7 (55.6-75.8)

II/III
15
84.0 (80.0-88.0)
7
64.9 (56.5-73.3)
19
56.2 (50.8-61.5)
7
50.5 (30.7-70.3)

III/IV
23
60.4 (49.8-70.9)
17
43.2 (31.7-54.6)
14
38.2 (24.7-51.6)
12
29.6 (17.8-41.4)

I/II/III
7
93.8 (90.4-97.2)
3
83.5 (70.9-96.1)
8
66.2 (57.4-75.0)
5
45.9 (13.6-78.2)

II/III/IV
10
74.8 (63.2-86.4)
4
70.6 (64.9-76.3)
6
51.9 (41.2-62.7)
3
46.7 (39.9-53.4)

I/II/III/IV
2
72.5 (53.9-91.1)
2
75.3 (67.4-83.1)
3
50.2 (25.9-74.4)
3
47.7 (0.6-94.1)










Borrmann style
I
5
93.2 (87.8-98.5)
2
96.4 (90.7-102.2)
6
75.0 (60.5-89.4)
16
55.9 (43.1-68.7)

II
5
91.8 (88.0-95.6)
2
74.6 (55.0-94.2)
6
73.4 (65.5-81.2)
16
52.3 (45.2-59.5)

III
5
77.6 (61.4-93.8)
2
77.7 (67.9-87.5)
6
47.7 (31.9-63.4)
16
35.7 (29.1-42.3)

IV
5
73.0 (49.6-96.4)
2
50.0 (23.8-76.2)
6
29.2 (22.8-35.5)
17
20.5 (15.0-26.0)

I/II
NA
NA
1
62.0 (52.5-71.5)
2
87.6 (82.3-92.9)
3
59.6 (50.5-68.7)

II/III
NA
NA
NA
NA
NA
NA
1
55.0 (49.5-60.5)

III/IV
NA
NA
1
45.0 (37.7-52.3)
2
45.5 (38.4-52.7)
3
38.1 (25.2-51.1)










Location
Upper
14
84.6 (80.1-89.2)
6
64.5 (54.5-74.6)
24
52.7 (46.4-58.9)
40
43.6 (38.7-48.5)

Middle
10
96.4 (80.1-92.8)
5
61.2 (41.2-81.1)
14
57.8 (51.4-64.3)
36
47.6 (42.1-53.1)

Lower
14
88.4 (85.0-91.8)
5
68.2 (57.4-78.9)
20
61.1 (53.7-68.5)
36
51.5 (46.5-56.5)

Entire
3
76.1 (67.0-85.2)
3
22.4 (0.3-44.5)
4
55.5 (23.0-87.9)
9
22.6 (18.6-26.5)

Mixed
4
70.6 (48.4-92.8)
1
67.0 (54.8-79.2)
7
46.4 (27.0-65.9)
12
36.1 (24.8-47.4)

EGJ
3
76.3 (42.6-110.1)
2
45.4 (0-97.3)
8
49.3 (32.8-65.9)
10
47.2 (22.5-71.9)










Site
Cardia
6
84.8 (76.2-93.4)
2
70.2 (40.8-99.6)
10
48.1 (37.9-58.2)
11
45.5 (35.0-56.0)

Cardia/Fundus
1
87.0 (79.6-94.4)
1
60.0 (46.0-74.0)
2
54.9 (35.7-74.2)
3
52.7 (45.1-60.2)

Fundus
1
97.0 (93.6-100.4)
NA
NA
2
56.8 (31.4-82.3)
3
42.9 (17.6-68.1)

Body
7
87.4 (79.8-94.9)
3
73.1 (53.8-92.5)
10
53.3 (42.9-63.7)
17
43.9 (37.7-50.1)

Body/Antrum
NA
NA
1
67.0 (54.8-79.2)
2
61.5 (51.7-71.3)
NA
NA

Antrum
9
86.3 (80.5-92.1)
3
71.0 (52.5-89.5)
1
58.8 (48.3-69.3)
15
48.6 (40.7-56.6)

Angle
NA
NA
NA
NA
1
81.0 (65.9-96.1)
1
27.0 (9.9-44.1)
Gastric stump










19
69.5 (59.8-79.2)
2
32.8 (46.3-49.4)
19
38.2 (30.6-45.9)
17
22.2 (15.6-28.8)










Metastasis
N0
13
93.4 (90.6-96.3)
1
98.0 (94.2-101.8)
24
78.6 (72.9-84.4)
45
67.8 (62.8-72.7)

N1/N2/N3
17
74.2 (67.7-80.8)
4
43.1 (21.2-65.0)
27
49.7 (42.3-57.1)
55
39.6 (35.0-43.6)

M1
30
53.4 (43.7-63.0)
15
24.7 (12.7-36.7)
18
16.5 (10.3-22.6)
18
8.4 (5.1-11.7)










Therapy
Surgery (S)
137
82.4 (80.6-84.2)
59
62.5 (54.9-70.0)
149
57.5 (53.3-61.6)
157
46.3 (42.9-49.8)

Chemotherapy (C)
53
61.0 (54.9-67.0)
26
46.2 (35.7-56.7)
26
53.7 (47.5-59.8)
16
42.3 (30.9-53.6)

Radiation (R)
2
38.9 (0-81.1)
NA
NA
NA
NA
NA
NA

S+C
75
77.6 (74.4-80.8)
39
55.3 (48.4-62.2)
72
55.5 (50.3-60.7)
46
44.7 (39.9-49.6)

S+R
2
77.3 (49.8-104.7)
1
73.0 (64.0-82.0)
1
64.0 (54.3-73.7)
NA
NA

C+R
5
58.3 (51.4-65.2)
3
35.1 (16.4-53.8)
NA
NA
NA
NA
S+C+R 5 79.6 (76.0-83.1) 4 51.9 (33.6-70.3) 5 37.5 (14.7-60.2) 4 32.9 (3.8-62.0)

N – numbers of included studies, SR – survival rate, CI – confidence interval, NA – not available, Combined – two or more styles, GA – gastric adenocarcinoma, SRCC – signet ring cell carcinoma, MC – mucinous adenocarcinoma, Tubular – tubular adenocarcinoma, TNM stage – tumour node metastasis stage, S+C, surgery + chemo; S+R – surgery + radiation, C+R – chemo + radiation, S+C+R – surgery + chemo + radiation, upper – upper one-third of the stomach, middle – middle one-third of the stomach, low – low one-third of the stomach, entire – entire stomach, mixed – two-third or more of the stomach, EGJ – esophagogastric junction